Back
  1. Home
  2. Profile of Deborah Crombez (UMONS)
Profil

Crombez Deborah

Main Referenced Co-authors
MULLER, Robert  (14)
BURTEA, Carmen  (13)
Scaux, Géraldine (5)
VANDER ELST, Luce  (5)
LAURENT, Sophie  (4)
Main Referenced Keywords
AMPK (4); diabetes (4); peptides (4); phage display (4); therapy (4);
Main Referenced Research Centers
CMMI - Centre de Recherche en Microscopie et Imagerie Médicale (14)
Main Referenced Disciplines
Immunology & infectious disease (8)
Endocrinology, metabolism & nutrition (7)
Pharmacy, pharmacology & toxicology (7)
Zoology (7)
Biotechnology (5)

Publications (total 14)

The most downloaded
135 downloads
Ansciaux, E., Burtea, C., Laurent, S., Crombez, D., Nonclercq, D., Vander Elst, L., & Muller, R. (05 June 2015). In vitro and in vivo characterization of several functionalized USPIO vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer's disease by molecular imaging. Contrast Media and Molecular Imaging, 10 (3), 211-224. doi:10.1002/CMMI.1626 https://hdl.handle.net/20.500.12907/16028

The most cited

39 citations (OpenAlex)

Ansciaux, E., Burtea, C., Laurent, S., Crombez, D., Nonclercq, D., Vander Elst, L., & Muller, R. (05 June 2015). In vitro and in vivo characterization of several functionalized USPIO vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer's disease by molecular imaging. Contrast Media and Molecular Imaging, 10 (3), 211-224. doi:10.1002/CMMI.1626 https://hdl.handle.net/20.500.12907/16028

Crombez, D., Vander Elst, L., Muller, R., & Burtea, C. (18 May 2016). Nouvelle stratégie thérapeutique du diabète de type 2 : activation de la voie AMPK via un agoniste peptidique des récepteurs de l'adiponectine [Poster presentation]. 9ème édition de la Matinée des Chercheurs 2016 (MdC2016), Valenciennes, France.

Crombez, D., Muller, R., & Burtea, C. (04 May 2016). Potential therapeutic peptides targeted to adiponectin receptors, able to modulate the AMPK pathway and regulate the glucose and lipid metabolism [Poster presentation]. Diabetes Kongress, Berlin, Germany.

Crombez, D., Muller, R., & Burtea, C. (04 May 2016). Potential therapeutic peptides targeted to adiponectin receptors, able to modulate the AMPK pathway and regulate the glucose and lipid metabolism [Paper presentation]. Diabetes Kongress, Berlin, Germany.

Crombez, D., Muller, R., & Burtea, C. (17 February 2016). Type 2 diabetes and metabolic syndrome : agonist peptides targeted to adiponectin receptors are new therapeutic strategy by activation of AMPK pathway [Poster presentation]. Belgian Peptide Group Meeting, Bruxelles, Belgium.

Ansciaux, E., Burtea, C., Laurent, S., Crombez, D., Nonclercq, D., Vander Elst, L., & Muller, R. (05 June 2015). In vitro and in vivo characterization of several functionalized USPIO vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer's disease by molecular imaging. Contrast Media and Molecular Imaging, 10 (3), 211-224. doi:10.1002/CMMI.1626
Peer Reviewed verified by ORBi

Crombez, D., Scaux, G., Muller, R., & Burtea, C. (22 May 2015). A metabolic therapy of Type 2 Diabetes : AMPK activation by agonist peptides targeted to adiponectin receptors [Poster presentation]. Journée d'études UMHAP - from lab to bedside, UMONS, Belgium.

Crombez, D., Scaux, G., Muller, R., & Burtea, C. (13 May 2015). A metabolic therapy of Type 2 Diabetes : AMPK activation by agonist peptides targeted to adiponectin receptors [Poster presentation]. Bioforum 2015- ULG, Liège, Belgium.

Crombez, D., Scaux, G., Muller, R., & Burtea, C. (10 March 2015). Development of an Adiponectin Receptor Agonist for the Metabolic Therapy of Type 2 Diabetes [Poster presentation]. 8ème édition de la Matinée des Chercheurs 2015 (MdC2015), Mons, Belgium.

Burtea, C., Laurent, S., Crombez, D., Delcambre, S., Sermeus, C., Millard, I., Rorive, S., Flamez, D., Beckers, M.-C., Salmon, I., Vander Elst, L., Eizirik, D., & Muller, R. (18 February 2015). Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)gamma-a as a highly specific biomarker of pancreatic beta cells. Contrast Media and Molecular Imaging, 10 (5), 398-412. doi:10.1002/cmmi.1641
Peer Reviewed verified by ORBi

Crombez, D., Laurent, S., Scaux, G., Vander Elst, L., Muller, R., & Burtea, C. (16 January 2015). Development of a molecular approach for the monitoring and treatment of diabetic patients [Poster presentation]. 7th annual meeting ISMRM Benelux, Ghent, Belgium.

Crombez, D., Scaux, G., Muller, R., & Burtea, C. (18 November 2014). Thérapie métabolique des troubles liés au diabète de type 2 via le développement d'un agoniste du récepteur de l'adiponectine [Poster presentation]. Biomarqueurs d'imagerie du métabolisme et du risque cardio-vasculaire, Lyon, France.

Stanicki, D., Boutry, S., Laurent, S., Wacheul, L., Nicolas, E., Crombez, D., Vander Elst, L., Lafontaine, D., & Muller, R. (03 March 2014). Carboxy-silane coated iron oxide nanoparticles: a convenient platform for cellular and small animal imaging. Journal of Materials Chemistry B, 2 (4), 387-397.
Peer Reviewed verified by ORBi

Crombez, D., Delcambre, S., Muller, R., & Burtea, C. (10 February 2014). Development of a peptide agonist of adiponectin receptor for the therapy of type 2 diabetes and metabolic syndrome [Poster presentation]. Belgian Peptide Meeting, Ghent, Belgium.

Crombez, D., Burtea, C., & Muller, R. (24 May 2013). Therapy of type 2 diabetes: development of an agonist of adiponectin receptor [Poster presentation]. 1st Health Institute Day, Mons, Belgium.

Contact ORBi UMONS